BeyondSpring Inc. (BYSI)

NASDAQ: BYSI · IEX Real-Time Price · USD
1.090
-0.010 (-0.91%)
At close: Feb 23, 2024, 4:00 PM
1.070
-0.020 (-1.83%)
After-hours: Feb 23, 2024, 4:39 PM EST

Company Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.

The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.

In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform.

The company was founded in 2010 and is headquartered in New York, New York.

BeyondSpring Inc.
BeyondSpring logo
Country United States
Founded 2010
IPO Date Mar 9, 2017
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Dr. Lan Huang Ph.D.

Contact Details

Address:
100 Campus Drive, West Side, 4th Floor, Suite 410
Florham Park, New Jersey 07932
United States
Phone 646-528-4184
Website beyondspringpharma.com

Stock Details

Ticker Symbol BYSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001677940
CUSIP Number G10830100
ISIN Number KYG108301006
SIC Code 2834

Key Executives

Name Position
Dr. Lan Huang Ph.D. Co-Founder, Chairman and Chief Executive Officer
Dr. G. Kenneth Lloyd Chief Scientific Officer
Linqing Jia Co-Founder
Stephen Kilmer Head of Investor Relations
Gregg Russo Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 6-K Report of foreign issuer
Jan 16, 2024 6-K Report of foreign issuer
Jan 10, 2024 6-K Report of foreign issuer
Dec 18, 2023 6-K Report of foreign issuer
Oct 30, 2023 6-K Report of foreign issuer
Oct 4, 2023 6-K Report of foreign issuer
Sep 20, 2023 6-K Report of foreign issuer
Jul 14, 2023 6-K Report of foreign issuer
May 12, 2023 6-K Report of foreign issuer